Some of the current examples of approved biomarkers for diagnosis are prostate-specific antigen (PSA) in prostate cancer or human epidermal growth factor receptor 2 (HER2) in breast cancer, in this latter case, being itself the target for therapeutic actions [31,32]. The gene discussed is ERBB2; the disease is prostate carcinoma.